🔎 Trials Near Me

Home › Coronary Artery Disease › NCT06271590

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

Recruiting

The MAGICAL SV Trial - A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Non Inferiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus-Coated Balloon in the Treatment of Small Vessels in Patients With Coronary Artery Disease.

Who can join

Ages 18 to 80 · All sexes

Full eligibility criteria
Clinical Inclusion Criteria:

1. Adult patient with an indication for PCI due to stable angina, NSTEACS, post-infarction angina or silent ischemia (in absence of symptoms a visually estimated target lesion diameter stenosis of ≥70%, a positive non-invasive stress test, FFR ≤0.80, or non-hyperemic pressure ratio \[NHPR\] ≤0.89 must be present)
2. Subject is ≥18 and \<80 years old
3. Subject is willing to comply with all protocol-required follow-up evaluations and provides written informed consent

   Angiographic Inclusion Criteria:
4. Target reference vessel diameter (visual estimation) ≤2.75 mm
5. Successful lesion preparation (residual stenosis \<30%), without flow-limiting complications (no or slow flow, dissection etc.)
6. Target lesion(s) in a native coronary artery
7. Up to two small vessel target lesions in two different vessels
8. Target lesion length (visual estimation): ≥6.0 and ≤34.0 mm and can be covered by a single 40 mm balloon
9. Target lesion diameter stenosis (visual estimation) \>30% and \<100% with Thrombolysis in Myocardial Infarction (TIMI) flow grade ≥2

Clinical Exclusion Criteria:

1. Planned (staged) intervention in the target vessel
2. ST-segment-elevation MI within 48 hours prior to index procedure
3. Subjects with acute cardiac decompensation or cardiogenic shock
4. Subject with a life expectancy of less than 24 months
5. Impaired renal function (glomerular filtration rate \[GFR\] \<30 mL/min)
6. Documented left ventricular ejection fraction (LVEF) ≤30%
7. Known allergies to acetylsalicylic acid, clopidogrel, prasugrel, ticagrelor, heparin, contrast medium, sirolimus or similar drugs (i.e., ABT-578 \[Zotarolimus\], biolimus, tacrolimus)
8. Relative or absolute contraindication to dual antiplatelet therapy (DAPT) for at least 1 month (e.g., planned surgeries that cannot be delayed)
9. Subject has an indication for chronic oral anticoagulation treatment and a contraindication for concomitant treatment with a P2Y12 inhibitor
10. If femoral access is planned, significant peripheral arterial disease which precludes safe insertion of a 6F sheath
11. Hemoglobin \<9 g/dL
12. Platelet count \<100,000 cells/mm3 or \>700,000 cells/mm3
13. White blood cell count \<3,000 cells/mm3
14. Active infection undergoing treatment
15. Clinically significant liver disease
16. Cerebrovascular accident (CVA) within 3 months or has any permanent neurological defect as a result of CVA
17. Subject is receiving oral or intravenous immunosuppressive therapy (e.g., inhaledsteroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)
18. Subject is unlikely to comply with the follow up requirements, per investigator's assessment
19. Subject currently enrolled in other investigational device or drug trial in which primary endpoint has not been reached
20. Pregnant and/or breast-feeding females or females who intend to become pregnant during the time of the study

    Angiographic Exclusion Criteria:

    All exclusion criteria apply to the target lesion(s) or target vessel(s)
21. Re-stenotic lesion(s), whether due to percutaneous old balloon angioplasty (POBA) or prior stenting
22. True bifurcation lesion (lesion involves both main and side branch\>2.5 mm) with planned treatment of both branches per investigator assessment
23. Angiographic evidence of thrombus in the target vessel
24. Myocardial bridging
25. Target lesion is heavily calcified
26. Diffuse distal disease to target lesion with impaired runoff, TIMI flow \<2
27. Non-target lesion in the target vessel requiring PCI

Note: Non-target vessel PCI is allowed at the time of index procedure if performed prior to study intervention and if successful and uncomplicated. For target lesions located in branches of the three main vessels (left anterior descending artery \[LAD\], left circumflex artery \[LCx\], right coronary artery \[RCA\]), the term target vessel refers to the branch and not the main vessel.

About the study

This is a multicenter, randomized, single-blind pivotal study to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels in patients with coronary artery disease. The objective is to establish the safety and efficacy of the Magic TouchTM Drug coated balloon in treatment of small vessels (≤2.75 mm).

A total of 1605 subjects will be enrolled in a maximum of 50 study sites located in North America. Additional sites located in Europe and South America may also participate in the study, with non-US sites contributing a maximum of \~50% of enrollees.

What is being tested

Sponsor: Concept Medical Inc. · Participants: 1,605 · Started: May 20, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06271590

Locations in the U.S.

ArizonaDignity Health - Mercy Gilbert Medical Center, Gilbert (Not yet recruiting)
CaliforniaCedars-Sinai Medical Center, Los Angeles (Not yet recruiting)
FloridaClearwater Cardiovascular and Interventional Consultants, Clearwater
University of Florida Health Sciences Center-Jacksonville, Jacksonville (Not yet recruiting)
Tallahassee Research Institute, Tallahassee (Not yet recruiting)
Tampa General Hospital / University of South Florida, Tampa (Not yet recruiting)
GeorgiaEmory University Hospital /Emory School of Medice, Atlanta (Not yet recruiting)
Atlanta VA Medical Center, Decatur (Not yet recruiting)
IllinoisLoyola University Medical Center, Maywood (Not yet recruiting)
MississippiNorth Mississippi Medical Center, Tupelo (Not yet recruiting)
New JerseyAtlanticare Regional Medical Center, Pomona
New YorkUniversity Hospitals, Cleveland Medical Center, Brooklyn (Not yet recruiting)
North Shore University Hospital - Northwell, Manhasset (Not yet recruiting)
Columbia University/NYP, New York (Not yet recruiting)
Icahn School of Medicine at Mount Sinai/ Mount Sinai Hospital, New York
Montefiore Medical Center, The Bronx
North CarolinaNC Heart and Vascular Research, LLC, Raleigh (Not yet recruiting)
OhioCleveland Clinic, Cleveland (Not yet recruiting)
University Hospitals, Cleveland Medical Center, Cleveland (Not yet recruiting)
OklahomaUniversity of Oklahoma Health Science Center, Oklahoma City (Not yet recruiting)
OregonProvidence St. Vincent Medical Center, Portland (Not yet recruiting)
PennsylvaniaUniversity of Pittsburgh Medical center (UPMC), Pittsburgh (Not yet recruiting)
TexasBaylor Scott & White The Heart Hospital - Plano, Plano
West VirginiaWest Virginia University Heart & Vascular Institute, Morgantown (Not yet recruiting)

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.